You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Thirty-day mortality in Candida bloodstream infection. Univariate analysis

From: Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis

  Total, n = 149 30-d Survivors, n = 93 30-d Non-survivors n = 56 p-value
Demographics
 Female 78 (52.3) 50 (53.7) 28 (50) 0.65
 Age, median (IQR) 47 (32–58) 44 (30–55) 48 (35.5–61.5) 0.23
 Intensive care unit admission 37 (24.8) 15 (16.1) 22 (39.2) < 0.001
 APACHE II n = 122, median (IQR) 18 (14–24) 16 (12–20) 23 (18.5–28.5) < 0.001
 Severe sepsis 66 (44.3) 29 (31.1) 37 (66) < 0.001
Comorbidities
 Hematologic neoplasia 45 (30.2) 22 (23.6) 23 (41) 0.025
 Solid neoplasia 26 (17.4) 17 (18.2) 9 (16) 0.73
 Cardiovascular 37 (24.8) 22 (23.6) 15 (26.7) 0.7
 Chronic kidney disease 18 (12) 10 (10.7) 8 (14.2) 0.52
 Cirrhosis 11 (7.3) 1 (1) 10 (17.8) < 0.001
 Diabetes mellitus 19 (12.7) 12 (12.9) 7 (12.5) 0.94
 Intra-abdominal infection 62 (41.6) 45 (48.3) 17 (30.3) 0.031
 Neutropenia 34 (22.8) 16 (17.2) 18 (32.1) 0.035
 Cancer CT 38 (25.5) 18 (19.3) 20 (35.7) 0.026
 CA-BSI 27 (18.1) 22 (23.6) 5 (8.9) 0.024
 CVC 123 (82.5) 80 (86) 43 (76.7) 0.15
 Early CVC removal 73 /123 (59.3) 55/80 (68.7) 18 /43 (41.8) 0.004
 Total parenteral nutrition 49 (32.8) 36 (38.7) 13 (23.2) 0.034
 Empiric antifungal therapy 35 (23.8) 27 (29.6) 8 (14.3) 0.033
 Steroid use 40 (26.8) 20 (21.5) 20 (35.7) 0.08
 Time to antifungal therapy median (IQR) 2 (1–3) 2 (1–2) 2 (1–3) 0.165
Initial treatment
 Echinocandin 64 (42.9) 42 (45.1) 22 (39.1) 0.48
 Caspofungin 43 (28.8) 27 (29) 16 (28.5) 0.89
 Anidulafungin 21 (14.1) 15 (16.1) 6 (11.3) 0.4
 AmB-d 61 (40.9) 35 (37.6) 26 (46.4) 0.29
 Azoles 25 (16.7) 16 (17.2) 9 (16) 0.85
 Fluconazole 24 (16.1) 15 (16.1) 9 (16) 0.95
 Voriconazole 1 (0.6) 1 (1)
Definitive treatment
 Echinocandin 56 (37.5) 36 (38.7) 20 (35.7) 0.71
 Caspofungin 31 (20.8) 17 (18.2) 14 (25) 0.34
 Anidulafungin 25 (16.7) 19 (20.4) 6 (10.7) 0.23
 AmB-d 46 (30.8) 21 (22.5) 25 (44.6) 0.005
 Azoles 47 (31.5) 36 (38.7) 11 (19.6) 0.015
 Fluconazole 41 (27.5) 31 (33.3) 10 (17.8) 0.4
 Voriconazole 6 (4) 5 (5.3) 1 (1.8) 0.27
 Inappropriate initial antifungal treatment 13 (8.7) 9 (9.6) 4 (7.1) 0.59
 Inappropriate definitive antifungal treatment 8 (5.3) 6 (6.4) 2 (3.5) 0.36
 Inappropriate initial and/or definitive treatment 16 (10.7) 11 (11.8) 5 (8.9) 0.58
 Non-albicans CBSI 89 (59.7) 62 (66.6) 27 (48.2) 0.026
C. tropicalis 35 (24) 19 (20) 16 (29) 0.25
C. glabrata 28 (19) 19 (20.4) 9 (16) 0.5
C. parapsilosis 16 (10.7) 15 (16) 1 (1.8) 0.006
  1. IQR interquartile range, APACHE acute physiology and chronic health evaluation, CT chemotherapy, CA-BSI catheter associated blood stream infection, CVC central venous catheter, AmB-d amphotericin B-deoxycholate, CBSI candida blood stream infection